… Effective treatments are still limited. The antifibrotic treatments pirfenidone and nintedanib
have been shown to slow disease progression as measured by annual rate of decline in …

… The UK restricts antifibrotic treatment to patients with a forced … The hypothesis of this study
is that antifibrotic treatment (… outcomes with regards to disease progression and survival. …

… We compared survival and disease progression between patients with IPF with Japanese
Respiratory Society (JRS) disease severity system stage I with and without oxygen …

… of antifibrotic drugs in reducing its progression and improving survival, that there should be
less doubt about treating … time of diagnosis, and antifibrotic treatment should be stopped only …

… a survival difference between patients treated with corticosteroids for ≥ 6 months and patients
who were not or treated … AF drugs are associated with a survival benefit in IPF and cannot …

… for antifibrotic drugs extending survival in patients with IPF by slowing disease progression,
… in mortality can be attributed to the use of antifibrotic therapy. Our findings are supported by …

… of renal fibrogenesis and the emerging anti-fibrotic drugs that have shown encouraging …
options and future directions in which anti-fibrotic treatments may be coupled with drugs that …

… patients with IPF who either were untreated or had not received effective treatments. Without
anti-fibrotic therapy, the overall survival rates for this condition are poor. Although limited by …

… with PEGPH20 in addition to chemotherapy experienced increased progression-free
survival as compared to patients treated with chemotherapy alone [64]. Further, the difference …

… antifibrotic therapies have been approved for the treatment of … studies, suggest that
antifibrotic therapies improve life … potential side-effects of antifibrotic drugs. There remains a …